PDF(Pubmed)
Abstract：
UNASSIGNED: While Immune checkpoint inhibition (ICI) therapy shows significant efficacy in metastatic melanoma, only about 50% respond, lacking reliable predictive methods. We introduce a panel of six proteins aimed at predicting response to ICI therapy.
UNASSIGNED: Evaluating previously reported proteins in two untreated melanoma cohorts, we used a published predictive model (EaSIeR score) to identify potential proteins distinguishing responders and non-responders.
UNASSIGNED: Six proteins initially identified in the ICI cohort correlated with predicted response in the untreated cohort. Additionally, three proteins correlated with patient survival, both at the protein, and at the transcript levels, in an independent immunotherapy treated cohort.
UNASSIGNED: Our study identifies predictive biomarkers across three melanoma cohorts, suggesting their use in therapeutic decision-making.
UNASSIGNED: Evaluating previously reported proteins in two untreated melanoma cohorts, we used a published predictive model (EaSIeR score) to identify potential proteins distinguishing responders and non-responders.
UNASSIGNED: Six proteins initially identified in the ICI cohort correlated with predicted response in the untreated cohort. Additionally, three proteins correlated with patient survival, both at the protein, and at the transcript levels, in an independent immunotherapy treated cohort.
UNASSIGNED: Our study identifies predictive biomarkers across three melanoma cohorts, suggesting their use in therapeutic decision-making.
摘要：
■虽然免疫检查点抑制（ICI）治疗在转移性黑色素瘤中显示出显着疗效，只有大约50%的人回答，缺乏可靠的预测方法。我们介绍了一组六种蛋白质，旨在预测对ICI治疗的反应。
■评估两个未经治疗的黑色素瘤队列中先前报道的蛋白质，我们使用已发表的预测模型(EaSIeR评分)来鉴定区分应答者和非应答者的潜在蛋白质.
最初在ICI组群中鉴定的六种蛋白质与未处理组群中的预测响应相关。此外,三种与患者生存相关的蛋白质，都是蛋白质，在成绩单上，在独立的免疫治疗治疗队列中。
■我们的研究确定了三个黑色素瘤队列中的预测性生物标志物，建议它们在治疗决策中的使用。
■评估两个未经治疗的黑色素瘤队列中先前报道的蛋白质，我们使用已发表的预测模型(EaSIeR评分)来鉴定区分应答者和非应答者的潜在蛋白质.
最初在ICI组群中鉴定的六种蛋白质与未处理组群中的预测响应相关。此外,三种与患者生存相关的蛋白质，都是蛋白质，在成绩单上，在独立的免疫治疗治疗队列中。
■我们的研究确定了三个黑色素瘤队列中的预测性生物标志物，建议它们在治疗决策中的使用。
